Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies-Reference-Cited by-同舟云学术

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

Published:2017-01-17 Issue:2 Volume:92 Page:e24615
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Costa Luciano J.¹,Maddocks Kami²,Epperla Narendranath³,Reddy Nishitha M.⁴,Karmali Reem⁵,Umyarova Elvira⁶,Bachanova Veronika⁷,Costa Cristiana⁸,Glenn Martha J.⁹,Chavez Julio C.¹⁰,Calzada Oscar¹¹,Lansigan Frederick⁸,Nasheed Hossain¹²,Barta Stefan K.¹²,Zhou Zheng¹³,Jaglal Michael¹⁰,Chhabra Saurabh⁶,Hernandez-Ilizaliturri Francisco¹⁴,Xavier Ana C.¹⁵,Mehta Amitkumar¹,Peker Deniz¹⁶,Forero-Torres Andreas¹,Al-Mansour Zeina¹⁷,Evens Andrew M.¹⁷,Cohen Jonathon B.¹¹,Flowers Christopher R.¹¹,Fenske Timothy S.³,Hamadani Mehdi³

Affiliation:

1. Division of Hematology and Oncology; University of Alabama at Birmingham; Birmingham Alabama USA

2. Division of Hematology; Ohio state University; Columbus Ohio USA

3. Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee Wisconsin USA

4. Division of Hematology and Oncology; Vanderbilt University; Nashville Tennessee USA

5. Division of Hematology, Oncology and Cell Therapy; Rush University; Chicago Illinois USA

6. Division of Hematology and Oncology; Medical University of South Carolina; Charleston South Carolina USA

7. Division of Hematology; Oncology and Transplantation, University of Minnesota; Minneapolis Minnesota USA

8. Department of Hematology and Oncology; Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire USA

9. Division of Hematology and Hematologic Malignancies; University of Utah; Salt Lake City Utah USA

10. Department of Malignant Hematology; H. Lee Moffitt Cancer Center and Research; Tampa Florida USA

11. Department of Hematology and Medical Oncology; Winship Cancer Institute; Atlanta Georgia USA

12. Department of Hematology/Oncology; Fox Chase Cancer Center; Philadelphia Pennsylvania USA

13. Division of Hematology-Oncology; University of Massachusetts; Worcester Massachusetts USA

14. Department of Medicine; Roswell Park Cancer Institute; Buffalo New York USA

15. Department of Pediatrics; University of Alabama at Birmingham; Birmingham Alabama USA

16. Department of Pathology; University of Alabama at Birmingham; Birmingham Alabama USA

17. Division of Hematology/Oncology; Tufts University; Boston Massachusetts USA

Publisher

Wiley

Subject

Hematology

Reference29 articles.

1. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol.,2006

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med.,2002

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol.,2006

4. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP;Sehn;Blood.,2007

5. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol.,2010

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CARs moving forward: The development of CAR T-cell therapy in the earlier treatment course of hematologic malignancies;Seminars in Hematology;2024-08

2. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy;Transplantation and Cellular Therapy;2024-07

3. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma;Expert Review of Anticancer Therapy;2024-06-03

4. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma;Journal for ImmunoTherapy of Cancer;2024-04

5. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy;Haematologica;2024-01-18